NASDAQ:BMRN

Biomarin Pharmaceutical Stock Insider Trading

Healthcare > Biotechnology

Buy BMRN

*Your capital is at risk

$60.02

-0.560 (-0.92%)

At Close: Jul 31, 2026

BioMarin Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 6.10. In total, the insiders bought 820.92K and sold 149.11K BMRN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	6.10
● Buy	820.92K shares
● Sell	149.11K shares
70% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 16, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Davis George Eric EVP, Chief Legal Officer	Officer	34 690 Value: $1.99M
Mar 16, 2026 Sell	Common Stock F-InKind	Davis George Eric EVP, Chief Legal Officer	Officer	7 177 Value: $419.9K
Mar 16, 2026 Buy	Common Stock A-Award	Davis George Eric EVP, Chief Legal Officer	Officer	14 570 Value: $836.8K
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Guyer Charles Greg EVP, Chief Technical Officer	Officer	35 680 Value: $2.05M
Mar 16, 2026 Buy	Common Stock A-Award	Guyer Charles Greg EVP, Chief Technical Officer	Officer	14 990 Value: $860.9K
Mar 13, 2026 Sell	Common Stock F-InKind	Hardy Alexander Chief Executive Officer	CEO / President	2 941 Value: $172.1K
Mar 13, 2026 Sell	Common Stock F-InKind	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	9 945 Value: $581.9K
Mar 13, 2026 Sell	Common Stock F-InKind	Guyer Charles Greg EVP, Chief Technical Officer	Officer	9 109 Value: $533.0K
Mar 11, 2026 Sell	Common Stock S-Sale	Guyer Charles Greg EVP, Chief Technical Officer	Officer	16 486 Value: $996.7K
Feb 26, 2026 Sell	Common Stock S-Sale	Davis George Eric EVP, Chief Legal Officer	Officer	26 061 Value: $1.60M
Feb 26, 2026 Sell	Common Stock S-Sale	Friberg Gregory R EVP, Chief R&d Officer	Officer	6 326 Value: $381.9K
Feb 25, 2026 Buy	Common Stock A-Award	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	6 683 Value: $410.6K
Feb 25, 2026 Buy	Common Stock A-Award	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	2 569 Value: $157.8K
Feb 25, 2026 Buy	Common Stock A-Award	Davis George Eric EVP, Chief Legal Officer	Officer	6 177 Value: $379.5K
Feb 25, 2026 Buy	Common Stock A-Award	Davis George Eric EVP, Chief Legal Officer	Officer	6 675 Value: $410.1K
Feb 25, 2026 Buy	Common Stock A-Award	Davis George Eric EVP, Chief Legal Officer	Officer	2 372 Value: $145.7K
Feb 25, 2026 Buy	Common Stock A-Award	Guyer Charles Greg EVP, Chief Technical Officer	Officer	6 176 Value: $379.5K
Feb 25, 2026 Buy	Common Stock A-Award	Guyer Charles Greg EVP, Chief Technical Officer	Officer	6 675 Value: $410.1K
Feb 25, 2026 Buy	Common Stock A-Award	Guyer Charles Greg EVP, Chief Technical Officer	Officer	2 371 Value: $145.7K
Feb 25, 2026 Buy	Common Stock A-Award	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	7 230 Value: $444.2K
Jan 20, 2026 Buy	Common Stock A-Award	Ramchandani Rashmi Virendra Vp, Chief Accounting Officer	Officer	7 070 Value: $398.1K
Jan 20, 2026 Buy	Common Stock A-Award	Ramchandani Rashmi Virendra Vp, Chief Accounting Officer	Officer	18 540 Value: $1.04M
Jan 20, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Ramchandani Rashmi Virendra Vp, Chief Accounting Officer	Officer	18 220 Value: $1.03M
Jan 20, 2026 Buy	Common Stock J-Other	Ramchandani Rashmi Virendra Officer	Officer	0 Value: $0
Dec 31, 2025 Buy	Common Stock J-Other	Mueller Brian Officer	Officer	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOMARIN PHARMACEUTICAL INC.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...

Read Full Profile Here